Stem Cells, Differation and Cancer Program

干细胞、分化与肿瘤计划由原细胞生长与分化演变而来 控制计划，包括研究B细胞生物学的前免疫肿瘤学计划的科学家 和淋巴系统恶性肿瘤。通过在以下地点成立干细胞研究所，进一步加强了该方案 爱因斯坦招募了四名癌症干细胞研究人员。有三个主要的研究主题 部分重叠：髓系白血病、淋巴系恶性肿瘤和干细胞生物学，并继续强调 在转录水平上的调控。虽然关注的焦点是血液系统的恶性肿瘤，但干细胞 研究延伸到肝脏、神经和乳腺干细胞。理查德·斯坦利博士是这项新研究的领导者 已配置的程序。任命内科科学家阿米特·维尔马博士为联合方案负责人和 血液学恶性疾病工作组的建立促进了翻译并增加了 相关和治疗性临床研究的数量。这项计划的目标是：(I)了解 干细胞前体细胞正常分化为成熟前体细胞过程中发生的分子事件； (Ii)识别在转录编程中发生的导致恶性表型的异常。 特别的，但不是唯一的，专注于血液系统的恶性肿瘤；(Iii)识别具有新的治疗作用的分子 疾病侵袭性的目标、指标或治疗反应报告；(4)翻译实验室 相关的研究成果，最终是治疗试验，并提高临床疗效 使用现有和新的化疗药物和生物制品的方案；以及(V)鼓励这些方案成员 他们在干细胞、细胞编程以及他们与癌症的关系方面有着共同的兴趣 彼此之间，以及其他项目的成员之间。人类组织研究得到了 收购两个致力于该项目的FACS Sorter生物安全系统--人类多能干细胞 人类胚胎和诱导多能干细胞开发和分析中心，该中心包括 干细胞制备单元、细胞分选和异种移植单元以及干细胞生物信息学单元。确实有 目前有31名计划成员，其中30名是初级成员；9名是爱因斯坦的新成员。研究得到支持 通过12笔NCI拨款(266万DC)和28笔其他与癌症相关的同行评审拨款(535万DC)。自2008年以来， 该计划成员发表了364份与癌症有关的出版物，其中16%代表内部，17%代表内部 代表方案间协作。

The Stem Cells, Differentiation and Cancer Program evolved from the former Cell Growth and Differentiation Control Program with the inclusion of scientists from the former Immuno-oncology program that study B cell biology and lymphoid malignancies. The program was further strengthened by the formation of a Stem Cell Institute at Einstein with the recruitment of four cancer stem cell investigators. There are three major research themes that partially overlap: the myeloid leukemias, lymphoid malignancies and stem cell biology, with a continued emphasis on regulation at the transcriptional level. While there is a focus on hematological malignancies, the stem cell research extends to hepatic, neural, and mammary stem cells. Dr. E. Richard Stanley is leader of this newly configured program. The appointment of Dr. Amit Verma, physician scientist, as Co-Program leader and the establishment of a Hematological Malignancies Working Group has catalyzed translation and increased the number of correlative and therapeutic clinical studies. The goals of this program are: (i) to understand the molecular events that occur during the normal differentiation of stem cell progenitors into their mature counterparts; (ii) to identify the aberrations that occur in transcriptional programming that result in the malignant phenotype with a special, but not sole, focus on the hematopoietic malignancies; (iii) to identify molecules that are novel therapeutic targets, indicators of aggressiveness of disease or reporters of response to treatment; (iv) to translate laboratory research findings into correlative and, ultimately, therapeutic trials and to enhance the effectiveness of clinical regimens with existing and new chemotherapeutics and biologicals; and (v) to encourage those Program members who share a common interest in stem cells, cellular programming, and their relationship to cancer to collaborate with each other and with the members of other programs. Human tissue research has been facilitated by the acquisition of two FACS Sorter Biosafety systems dedicated to this program, a Human Pluripotent Stem Cell Center for the development and analysis of human embryonic and induced pluripotent stem cells that comprises a stem cell preparation unit, a cell sorting and xenotransplantation unit, and a stem cell bioinformatics unit. There are currently 31 program members of whom 30 are primary; nine are new recruits to Einstein. Research is supported by 12 NCI grants ($2.66M DC) and 28 other cancer-relevant peer reviewed grants ($5.35M DC). Since 2008, there have been 364 cancer-relevant publications by members of this program, of which 16% represent intra- and 17% represent inter-programmatic collaborations.